Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Core Insights - Cullinan Therapeutics, Inc. is participating in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 9:30 a.m. ET [1][2] Company Overview - Cullinan Therapeutics is a biopharmaceutical company focused on developing targeted therapies for autoimmune diseases and cancer, with a diversified portfolio of clinical-stage assets [3] - The company aims to create new standards of care by inhibiting key disease drivers and harnessing the immune system to eliminate diseased cells [3] - Cullinan's approach includes rigorous candidate selection and development processes to fast-track promising therapeutic molecules [3]